genetic testing
According to the bankruptcy petition, the company has liabilities of $1 billion to $10 billion and assets of $500 million to $1 billion.
At HIMSS23, panelists discussed how genomics could improve patient care and the challenges to implementing genetic testing programs.
This marks the company's second deal this year. It announced plans to acquire a network of fertility clinics in February.
The test reports on the G84E mutation in the HOXB13 gene, which studies have shown increase a person’s risk of developing prostate cancer.
The deal is expected to close by the end of 2021.
Invitae said the acquisition will provide patients with a centralized hub for their genomic and clinical data.
SNP chip data often reported by consumer genomics companies should not be considered for clinical decisions without additional validation, warn researchers.
The consumer genomics company's existing offering, called AncestryHealth, sold clinician-ordered tests that were not cleared or approved by the FDA.
Flare Capital Partners offers an overview of sequencing options, opportunities for integration into clinical workflow and the companies making that happen.
The Israel-based company is offering 11 genetic risk tests, three polygenic risk tests and 15 carrier status reports.